Clinical utility of telavancin for treatment of hospital-acquired pneumonia: focus on non-ventilator-associated pneumonia

por Rubinstein, Ethan, Stryjewski, Martin E, Barriere, Steven L
Publicado 2014

Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment

por Worboys, Philip D., Wong, Shekman L., Barriere, Steven L.
Publicado 2015

Reply to Tarchini

por Rubinstein, Ethan, Corey, G. Ralph, Stryjewski, Martin E., Barriere, Steven L.
Publicado 2011

Potential Role for Telavancin in Bacteremic Infections Due to Gram-Positive Pathogens: Focus on Staphylococcus aureus

por Corey, G. Ralph, Rubinstein, Ethan, Stryjewski, Martin E., Bassetti, Matteo, Barriere, Steven L.
Publicado 2015

Effect of vancomycin serum trough levels on outcomes in patients with nosocomial pneumonia due to Staphylococcus aureus: a retrospective, post hoc, subgroup analysis of the Phase 3...

por Barriere, Steven L, Stryjewski, Martin E, Corey, G Ralph, Genter, Fredric C, Rubinstein, Ethan
Publicado 2014

Assessment of Minimum Inhibitory Concentrations of Telavancin by Revised Broth Microdilution Method in Phase 3 Hospital-Acquired Pneumonia/Ventilator-Associated Pneumonia Clinical...

por Smart, Jennifer I., Corey, Gordon Ralph, Stryjewski, Martin E., Wang, Whedy, Barriere, Steven L.
Publicado 2016

Telavancin in Hospital-Acquired and Ventilator-Associated Pneumonia (HAP/VAP) Caused by Staphylococcus aureus: Post Hoc Analysis of 2 Randomized, Controlled Trials

por Niederman, Michael S., Lee, Patrick C., Barriere, Steven L., Barnes, Chris N., Castaneda-Ruiz, Bibiana
Publicado 2019

A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study

por Stryjewski, Martin E, Lentnek, Arnold, O’Riordan, William, Pullman, John, Tambyah, Paul Anantharajah, Miró, Jose M, Fowler Jr, Vance G, Barriere, Steven L, Kitt, Michael M, Corey, G Ralph
Publicado 2014

Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive Pathogens

por Rubinstein, Ethan, Lalani, Tahaniyat, Corey, G. Ralph, Kanafani, Zeina A., Nannini, Esteban C., Rocha, Marcelo G., Rahav, Galia, Niederman, Michael S., Kollef, Marin H., Shorr, Andrew F., Lee, Patrick C., Lentnek, Arnold L., Luna, Carlos M., Fagon, Jean-Yves, Torres, Antoni, Kitt, Michael M., Genter, Fredric C., Barriere, Steven L., Friedland, H. David, Stryjewski, Martin E.
Publicado 2011